

## REGISTER OF INTERESTS

SIGN position statement: Use of long-acting buprenorphine for opioid substitution therapy

Published: 06/04/2022

05 April 2022

	Financial		Non-financial		Non-personal	Any other interest of relevance	Date received by SIGN Executive	Action
	Specific	Non-Specific	Specific	Non-Specific				
<b>CHAIR</b>								
Professor Angela Timoney, Chair, SIGN	None	Pharmacy management – Management board (ceased 2021)	None	None	None	None	23.2.22	No action required
<b>GROUP MEMBERS</b>								
Mithun Barik, Addiction Psychiatrist, South Community Addiction Team, NHS Ayrshire and Arran	None	None	Prescribing long-acting buprenorphine - NHS Ayrshire and Arran (South Community Addiction Team). No funding received from manufacturer - free training sessions and	None	None	Trustee (no direct clinical role) - River Garden Auchincruive, Ayr (A long stay addiction rehab run by the charity Independence from Drug and Alcohol Scotland) – non-specific ((Related to	14.1.22	The declared personal, non-financial, specific interest is not considered to represent a significant risk of bias and the member is allowed to participate fully.

## REGISTER OF INTERESTS

SIGN position statement: Use of long-acting buprenorphine for opioid substitution therapy

Published: 06/04/2022

05 April 2022

			leaflets were provided.			addiction and reducing drug death))		
Lisa Buchan, Practice Mental Health Nurse, The Access Place, NHS Lothian	The Access Place	None	None	None	None	None	24.1.22	No action required
Sarah Buchan, Pharmaceutical Services Improvement and Development Manager, NHS Grampian	None	None	None	None	None	None	21.1.22	No action required
Thomas Byrne, National Prisons Pharmacy Adviser/ Pharmacist,	None	None	Presented on development of LAB pilot in Scotland at SMMGP meeting (now known as Addiction	Pharmaceutical Society – Regulator Royal Pharmaceutical Society - Professional Body	None	Poster accepted for conference in March 2022. Poster will only be presented if author attends. HIS ET have not confirmed attendance at	12.1.22	The declared personal, non-financial, specific interest is not considered to represent a significant risk of bias and the

## REGISTER OF INTERESTS

SIGN position statement: Use of long-acting buprenorphine for opioid substitution therapy

Published: 06/04/2022

05 April 2022

Healthcare Improvement Scotland			Professionals) ceased 2020.  Included as useful contact in Scottish Government <i>Guidance for the use of Buprenorphine for Opiate Substitution Treatment in Prisons during the Covid-19 Pandemic.</i>			this international conference - International Forum on Quality and Safety in Healthcare – (specific).		member is allowed to participate fully.
Lesley Campbell, Team Lead, Drug and Alcohol Recovery Service, NHS Highland	None	None	None	None	None	None	24.1.22	No action required
Tracey Clusker, Clinical Lead Nurse Consultant,	Nothing declared	Nothing declared	Nothing declared	Nothing declared	Nothing declared	Nothing declared	10.1.22	No action required

## REGISTER OF INTERESTS

SIGN position statement: Use of long-acting buprenorphine for opioid substitution therapy

Published: 06/04/2022

05 April 2022

MAT Standards Implementation Support Team, Public Health Scotland								
Dr Steve Conroy, Lead Medical Practitioner Community Prescribing Service, NHS Lanarkshire	Presentation (once only) – Camurus.  Presentation (once only) – Indivior.	None	None	None	None	None	13.1.22	Waiver to participate completed
Fiona Cowden, Consultant Psychiatrist, Addiction Psychiatry, NHS Tayside	Nothing declared	Nothing declared	Principal Investigator for the EXPO Study, Tayside site. Randomised controlled study of CTIMP depot buprenorphine injection (Sublocade) v treatment as usual - Sponsor Kings College London / South	Nothing declared		I responded to email queries to my service from the local MSP regarding opiate substitution treatment choices for patients, and highlighted that SMC restrictions and MAT standards for buprenorphine are not aligned.	24.12.21	The declared personal, non-financial, specific interest is not considered to represent a significant risk of bias and the member is allowed to participate fully.

## REGISTER OF INTERESTS

SIGN position statement: Use of long-acting buprenorphine for opioid substitution therapy

Published: 06/04/2022

05 April 2022

			London and Maudsley NHS Foundation Trust. Non-commercial study – current			The MSP corresponded with the Minister regarding this – NHS Tayside – ceased 9.8.21 (specific).		
Jessica Davidson, Clinical Lead Nurse (Justice) MAT Standards Implementation Support Team, NHS Lothian/ Scottish Government	None	None	None	None	None	None	10.1.22	No action required
Sarah Donaldson, Specialist Pharmacist in Substance Use, NHS Tayside	None	None	I am a researcher in the NHS Tayside sponsored study “Agent for recovery: The opportunity for enhancing social inclusion afforded by prolonged	None	None	None	21.12.21	The declared personal, non-financial, specific interest is not considered to represent a significant risk of bias and the member is allowed to

**REGISTER OF INTERESTS**

SIGN position statement: Use of long-acting buprenorphine for opioid substitution therapy

Published: 06/04/2022

05 April 2022

			release buprenorphine formulations” Chief Investigator: Dr Andrew Radley Funded as an investigator initiated study agreement between Camurus AB, University of Dundee and NHS Tayside – (specific).					participate fully.
Professor Michael Eddleston, Honorary Consultant and Professor of Clinical Toxicology, University of Edinburgh and NHS Lothian	None	Consultancy – Micropharm Ltd	None	None	None	None	10.1.22	The declared personal, financial, non-specific interest is not considered to represent a significant risk of bias and the member is allowed to participate fully.

**REGISTER OF INTERESTS**

SIGN position statement: Use of long-acting buprenorphine for opioid substitution therapy

Published: 06/04/2022

05 April 2022

Dr Emma Fletcher, Director of Public Health, NHS Tayside	None	None	None	Public Health Directorate are responsible for convening and chairing the Tayside Drug Death Review Group. The annual report is publicly available at <a href="https://www.nhstayside.scot.nhs.uk/OurServices/AZ/PublicHealth/PR_OD_213564/index.htm">https://www.nhstayside.scot.nhs.uk/OurServices/AZ/PublicHealth/PR_OD_213564/index.htm</a> - NHS Tayside		None	19.1.22	No action required
Martin Graham, Development Officer, Living Experience, Scottish Drugs Forum	None	None	None	None	None	None	26.1.22	No action required
Cara Halliday, Mental Health	None	None	None	None	None	None	24.1.22	No action required

## REGISTER OF INTERESTS

SIGN position statement: Use of long-acting buprenorphine for opioid substitution therapy

Published: 06/04/2022

05 April 2022

Nurse and Team Leader, NHS Forth Valley and Her Majesty's Prison Glenochil								
Kelly Hamilton, Prison Healthcare Addictions Team, NHS Forth Valley	None	None	None	None	None	None	19.1.22	No action required
Duncan Hill, Specialist Pharmacist in Substance Misuse, NHS Lanarkshire	None	Delivery of educational presentations relating to substance misuse – honoraria – PCMS (generic & impartial)	None	None	None	None	6.1.22	The declared personal, financial, non-specific interest is not considered to represent a significant risk of bias and the member is allowed to participate fully.



**REGISTER OF INTERESTS**

SIGN position statement: Use of long-acting buprenorphine for opioid substitution therapy

Published: 06/04/2022

05 April 2022

Andrew Horne, Executive Director, We Are With You Scotland	None	None	None	None	None	<u>Personal statement</u>  We Are With You is the largest charity provider of drug and alcohol services in Scotland. We are in touch with thousands of people with drug and alcohol problems across the country. I am the executive lead for the charity in Scotland. I am an advisor to the government on drug and alcohol related issues. I am committed to improving choice for people coming into treatment and thus improving the quality of the treatment offer. My organisation has been trialling	31.1.22	No action required
------------------------------------------------------------	------	------	------	------	------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------	--------------------

## REGISTER OF INTERESTS

SIGN position statement: Use of long-acting buprenorphine for opioid substitution therapy

Published: 06/04/2022

05 April 2022

						Buvidal in England and thus we have some valuable insights as to effectiveness.		
Lynn Laverty, Clinical Nurse Specialist, NHS Greater Glasgow and Clyde	None	None	None	None	None	None	25.1.22	No action required
Heather MacLeod, Addiction Community Psychiatric Nurse, NHS Highland	None	None	None	None	None	None	19.1.22	No action required
Pauline MacLeod, Advanced Nurse Practitioner, Drug and Alcohol Service, NHS Highland	None	None	None	None	None	None	20.1.22	No action required

## REGISTER OF INTERESTS

SIGN position statement: Use of long-acting buprenorphine for opioid substitution therapy

Published: 06/04/2022

05 April 2022

Paul Maguiness, Lead Pharmacist for Substance Misuse and Prison Services, NHS Lothian	None	None	None	None	None	None	12.1.22	No action required
David Morrison, Lead Clinical Pharmacist, Adult Mental Health and Learning Disabilities, NHS Tayside	None	None	None	None	None	None	14.1.22	No action required
Dr Colin Rae, Consultant in Anaesthesia and Pain Management, NHS Greater Glasgow and Clyde	None	None	None	None	None	None	6.1.22	No action required

## REGISTER OF INTERESTS

SIGN position statement: Use of long-acting buprenorphine for opioid substitution therapy

Published: 06/04/2022

05 April 2022

Trina Ritchie, Lead Clinician, Alcohol and Drug Recovery Services, NHS Greater Glasgow and Clyde	Consultancy services including advisory boards – Camurus Ltd – (ceased Sept 2021)	Nothing declared	Nothing declared	Nothing declared	Nothing declared	Nothing declared	12.12.21	Waiver to participate completed
Linda Smith, Drug Liaison Nurse, Harm Reduction Team, NHS Lothian	None	None	None	None	None	None	24.1.22	No action required
James Tidder, Consultant in Addictions Psychiatry and Clinical Lead, Borders Addiction Service, NHS Borders	One off honoraria received for participation in brand awareness exercise – Camurus (ceased Sept 2021).	None	Received offer of support for publication of a case series looking at the use of long- acting injectable buprenorphine for detox - Opi- Assist  Opi-Assist is funded by Camurus Ltd,	None	None	None	19.1.22	Waiver to participate completed

## REGISTER OF INTERESTS

SIGN position statement: Use of long-acting buprenorphine for opioid substitution therapy

Published: 06/04/2022

05 April 2022

			but is run independently and the company has no influence over the process or decisions of the steering committee. Opi-Assist offers writing support to help healthcare professionals to publish research on opiate addiction (ongoing).					
Emily Traynor, Service Manager, Alcohol and Drug Recovery Service, NHS Lothian	None	None	None	None	None	None	20.1.22	No action required
Jason Wallace, Senior	None	None	None	None	None	None	12.1.22	No action required

## REGISTER OF INTERESTS

SIGN position statement: Use of long-acting buprenorphine for opioid substitution therapy

Published: 06/04/2022

05 April 2022

Development Officer, Scottish Drugs Forum								
Judith Wilson, Lead Clinician in Pain Management, Consultant in Anaesthesia and Pain Management, NHS Forth Valley	None	None	None	None	None	None	10.1.22	No action required